ITCI250117C72500
- 0.00
- 0.000.00%
Intra-Cellular Therapies Newsroom
Why Intra-Cellular Therapies, Inc. (ITCI) Dominated Last Week's Rally
Catalyst Watch: Netflix Earnings, Monster Beverage Event, Drug Data, and Quantum Volatility
Johnson & Johnson Q4 EPS, Revenue Estimates Nudged Higher, BofA Says
US MOVERS&SHAKERS Jan 13-Jan 17, 2025
JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference
Johnson & Johnson Ratings Put On CreditWatch Negative by S&P Global
Intra-Cellular Therapies Analyst Ratings
Daily short sale tracking: Maplebear's short volume increased by 9 million, with a short sale ratio of 38%
Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer
A Quick Look at Today's Ratings for Intra-Cellular Therapies(ITCI.US), With a Forecast Between $118 to $140
Johnson & Johnson's Strategic Acquisition of Intra-Cellular Therapies: Balancing Short-term Dilution With Long-term Growth Potential
Express News | Intra-Cellular Therapies Inc : Leerink Partners Raises Target Price to $132 From $100
Express News | Intra-Cellular Therapies Inc : Piper Sandler Cuts to Neutral From Overweight
Shareholder Alert: Ademi LLP Investigates Whether Intra-Cellular Therapies, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Top Gap Ups and Downs on Monday: DELL, RACE, CVS and More
These Stocks Are Moving the Most Today: Micron, Intra-Cellular Therapies, and More -- Barrons.com
Wall Street Today: Market Turns Around, Let's See if it Lasts
12 Health Care Stocks Moving In Monday's Pre-Market Session
Baird Downgrades Intra-Cellular Therapies to Neutral From Outperform, $132 Price Target
Equities Mixed Intraday as Markets Await Bank Earnings, Inflation Data